Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer.
暂无分享,去创建一个
Chau Dang | Mark Robson | Matthew Paulson | Larry Norton | D. Lake | C. Hudis | L. Norton | M. Theodoulou | H. Rugo | B. Yeh | M. Robson | John W. Park | T. Traina | A. Seidman | M. Dickler | S. Patil | Hope S Rugo | John W Park | J. Caravelli | Andrew D Seidman | Benjamin Yeh | Sujata Patil | C. Dang | M. Melisko | Monica Fornier | Clifford A Hudis | Diana Lake | Tiffany A Traina | James F Caravelli | Michele E Melisko | Stephanie Geneus | Jill Grothusen | Maria Theodoulou | Carlos D Flombaum | Maura N Dickler | M. Fornier | C. Flombaum | J. Grothusen | S. Geneus | Matthew L. Paulson
[1] Melissa Bondy,et al. Residual risk of breast cancer recurrence 5 years after adjuvant therapy. , 2008, Journal of the National Cancer Institute.
[2] R K Jain,et al. Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[3] H. Schnaper,et al. Estrogen promotes angiogenic activity in human umbilical vein endothelial cells in vitro and in a murine model. , 1995, Circulation.
[4] E. Perez,et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. , 2007, The New England journal of medicine.
[5] G. Sledge,et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. , 2003, Seminars in oncology.
[6] P. Lønning,et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer* , 2004, The New England journal of medicine.
[7] J. Forbes,et al. Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] R. Henriksson,et al. Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] J. Cuzick,et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial , 2002, The Lancet.
[10] E. Perez,et al. A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer , 2003 .
[11] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[12] A. Brodie,et al. Estrogen regulates vascular endothelial growth/permeability factor expression in 7,12-dimethylbenz(a)anthracene-induced rat mammary tumors. , 1996, Endocrinology.
[13] V. Craig Jordan,et al. In vitro regulation of vascular endothelial growth factor by estrogens and antiestrogens in estrogen-receptor positive breast cancer , 2002, Breast cancer.
[14] N. Ferrara,et al. The biology of VEGF and its receptors , 2003, Nature Medicine.
[15] E. Voest,et al. The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway. , 2008, Current clinical pharmacology.
[16] R. Schiff,et al. Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. , 2005, Clinical Cancer Research.
[17] R. Busse,et al. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation , 1999, Nature.
[18] C. Estilo,et al. Osteonecrosis of the jaw related to bevacizumab. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] Catherine Legrand. 1687Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials : Early Breast Cancer Trialists' Collaborative Group (EBCTCG) , 2005 .
[20] C. Davies. Switching to exemestane after 2-3 years of adjuvant tamoxifen prolongs disease-free survival, but not overall survival, in postmenopausal women surviving primary breast cancer, compared with continuous tamoxifen. , 2004, Cancer treatment reviews.
[21] C. Hudis,et al. Osteonecrosis of the jaw (ONJ) among intravenous (IV) bisphosphonate- and/or bevacizumab-treated patients (pts) at Memorial Sloan-Kettering Cancer Center (MSKCC) , 2008 .
[22] E. Perez,et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] P. Span,et al. Vascular endothelial growth factor is associated with the efficacy of endocrine therapy in patients with advanced breast carcinoma , 2003, Cancer.
[24] C. Boni,et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] A. Buzdar,et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] J. Forbes,et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] C. Alpers,et al. VEGF inhibition and renal thrombotic microangiopathy. , 2008, The New England journal of medicine.
[28] J. Foidart,et al. Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences. , 2003, The Journal of clinical endocrinology and metabolism.
[29] B. Hennig,et al. Antiestrogens inhibit endothelial cell growth stimulated by angiogenic growth factors. , 1996, Anticancer research.
[30] J. Isner,et al. Estrogen and Angiogenesis: A Review , 2001, Arteriosclerosis, thrombosis, and vascular biology.
[31] R. Schiff,et al. Unraveling the Mechanisms of Endocrine Resistance in Breast Cancer: New Therapeutic Opportunities , 2007, Clinical Cancer Research.
[32] P Kelly Marcom,et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] M. Morgan,et al. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] H. Schoder,et al. Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy. , 2008, The oncologist.
[35] Jenny M. Jones,et al. Chromatin immunoprecipitation analysis of gene expression in the rat uterus in vivo: estrogen-induced recruitment of both estrogen receptor alpha and hypoxia-inducible factor 1 to the vascular endothelial growth factor promoter. , 2005, Molecular endocrinology.
[36] R. Simon,et al. Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.
[37] W. Dahut,et al. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[38] Y Wang,et al. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.